Checkpoint Competitors

Delisted . USA . 
Stock . Checkpoint Therapeutics
CKPTDelisted Stock  USD 4.26  0.02  0.47%   
Checkpoint Therapeutics competes with Climb Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Checkpoint Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Checkpoint Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Checkpoint Therapeutics vs Inozyme Pharma Correlation

Very weak diversification

The correlation between Checkpoint Therapeutics and INZY is 0.5 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Checkpoint Therapeutics and INZY in the same portfolio, assuming nothing else is changed.

Moving together with Checkpoint Stock

  0.75GPOVF Grupo Carso SABPairCorr

Moving against Checkpoint Stock

  0.65ORGN Origin MaterialsPairCorr
  0.61HPQ HP Inc Aggressive PushPairCorr
  0.35UIS UnisysPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
4.264.264.26
Details
Intrinsic
Valuation
LowRealHigh
3.223.224.69
Details
Naive
Forecast
LowNextHigh
4.484.484.48
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
4.084.164.24
Details

Checkpoint Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Checkpoint Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Checkpoint and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Checkpoint Therapeutics does not affect the price movement of the other competitor.

High positive correlations

INZY
+ 0.88
CLYM
INZY
+ 0.7
SCPH
INZY
+ 0.58
VIGL
CLYM
+ 0.57
VIGL
SCPH
+ 0.57
VIGL
SCPH
+ 0.53
CLYM
  

High negative correlations

INZY
- 0.0
SLGC
INZY
- 0.0
ITOS
SLGC
- 0.0
ITOS
INZY
- 0.0
YMAB
SLGC
- 0.0
YMAB
ITOS
- 0.0
YMAB

Risk-Adjusted Indicators

There is a big difference between Checkpoint Stock performing well and Checkpoint Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Checkpoint Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VIGL  7.50  3.90  0.82 (0.58) 1.63 
(9.75)
 5.09 
(2.49)
 241.38 
ORTX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
RVNC  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CLYM  6.03  1.68  0.29  2.12  5.02 
(7.36)
 14.49 
(8.38)
 42.56 
GTHX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
SCPH  2.39  0.59  0.17  36.69  2.34 
(2.79)
 7.28 
(4.75)
 17.14 
YMAB  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
ITOS  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
SLGC  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
INZY  8.04  3.33  0.60  1.37  3.27 
(11.66)
 10.42 
(7.26)
 179.17 

Checkpoint Therapeutics Competitive Analysis

The better you understand Checkpoint Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Checkpoint Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Checkpoint Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CKPT VIGL RVNC CLYM SCPH YMAB ITOS INZY
 0.47 
 4.26 
Checkpoint
 0.00 
 8.05 
Vigil
 0.00 
 3.65 
Revance
 1.94 
 5.05 
Climb
 0.18 
 5.67 
Scpharmaceuticals
 0.00 
 8.61 
YMAB
 0.00 
 10.15 
Iteos
 0.00 
 4.00 
Inozyme
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Risky
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Solid
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Hazard
Hazard
Fair
Hazard
Hazard
Hazard
Hazard
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Not Rated
Cautious Hold
Not Rated
Not Rated
Not Rated
Not Rated
Current Ratio
1.30 X
21.35 X
3.38 X
N/A
3.72 X
5.23 X
6.42 X
14.54 X
Net Asset
7.47 M
117.69 M
478.45 M
217.19 M
107.52 M
119.9 M
686.98 M
123.18 M
Profit Margin
N/A
N/A
(0.72) %
N/A
(1.84) %
(0.26) %
N/A
N/A
EBITDA
(56.17 M)
(83.8 M)
(290.64 M)
(30.36 M)
(77.43 M)
(30.67 M)
(121.82 M)
(104.03 M)
Current Valuation
337.66 M
321.16 M
680.39 M
236.19 M
315.46 M
332.06 M
(61.62 M)
220.43 M
Price To Book
22.75 X
9.11 X
12.30 X
1.99 X
28.45 X
4.47 X
0.91 X
8.12 X
Operating Margin
N/A
N/A
(0.54) %
N/A
(0.89) %
(0.29) %
N/A
N/A
Retained Earnings
(370.57 M)
(307.03 M)
(2.08 B)
(229.88 M)
(366.49 M)
(487.14 M)
(9.78 M)
(387.95 M)
Current Asset
46.85 M
N/A
208.68 M
N/A
N/A
N/A
N/A
N/A
Beta
1.14
3.34
0.95
-0.15
0.3
0.53
1.49
2.29
Number Of Employees
24
67
597
17
162
104
173
67
Shares Outstanding
86.32 M
46.67 M
104.39 M
47.74 M
53.68 M
45.44 M
44.21 M
64.56 M
Cash Flow From Operations
(31.1 M)
(51.22 M)
(216.57 M)
(15.56 M)
(70.54 M)
(15.71 M)
(98.18 M)
(91.91 M)
Total Debt
20.1 M
12.95 M
478.43 M
532 K
52.69 M
820 K
5.1 M
46.87 M
Return On Equity
-18.7
-1.46
-20.97
-0.26
-9.34
-0.24
-0.35
-1.42
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-1.53
-0.62
-0.24
-0.17
-0.57
-0.0867
-0.18
-0.48
Number Of Shares Shorted
2.96 M
447.39 K
4.51 M
1.8 M
811.77 K
1.85 M
2.06 M
3.38 M
Book Value Per Share
0.20 X
0.86 X
(1.55) X
2.60 X
(0.40) X
1.93 X
12.90 X
0.49 X
Current Liabilities
2.89 M
N/A
17.52 M
N/A
N/A
N/A
N/A
N/A
Total Asset
7.47 M
117.69 M
478.45 M
217.19 M
107.52 M
119.9 M
686.98 M
123.18 M
Debt To Equity
0.1 %
0 %
2.94 %
N/A
0.32 %
0.02 %
0.01 %
0.02 %
Short Ratio
3.18 X
0.56 X
1.70 X
0.80 X
0.36 X
1.00 X
1.34 X
0.78 X
Target Price
4.45
8.0
9.47
9.5
5.68
8.6
10.35
4.0
Shares Owned By Institutions
42.18 %
69.90 %
87.45 %
43.34 %
80.35 %
82.77 %
90.28 %
94.29 %
Market Capitalization
370.71 M
375.71 M
381.02 M
351.15 M
304.36 M
391.22 M
448.68 M
258.25 M
Price To Earning
(7.60) X
N/A
(7.60) X
N/A
N/A
N/A
50.50 X
N/A
Price To Earnings To Growth
N/A
N/A
(0.64) X
N/A
N/A
0.04 X
N/A
(0.06) X
Price To Sales
9,042 X
N/A
1.48 X
N/A
6.09 X
4.58 X
12.78 X
N/A
Net Income
(56.24 M)
(84.26 M)
(323.99 M)
(73.9 M)
(85.15 M)
(29.67 M)
(134.41 M)
(102.02 M)
Earnings Per Share
(1.28) X
(2.10) X
(3.34) X
(0.59) X
(1.81) X
(0.50) X
(4.73) X
(1.68) X
Shares Owned By Insiders
14.05 %
18.16 %
8.55 %
0.79 %
5.97 %
11.97 %
0.34 %
1.26 %
Revenue
41 K
N/A
234.04 M
N/A
36.33 M
87.69 M
35 M
N/A
Working Capital
(12.62 M)
66.44 M
249.64 M
149.94 M
90.97 M
74.81 M
469.18 M
86.78 M
Cash And Equivalents
30.89 M
148.91 M
233.82 M
N/A
55.85 M
133.66 M
791.86 M
151.48 M
Cash Per Share
0.33 X
5.27 X
3.20 X
N/A
2.04 X
3.06 X
22.26 X
3.77 X
Gross Profit
(31.4 M)
N/A
103.69 M
N/A
34.21 M
69.58 M
N/A
N/A
Day Typical Price
4.26
8.05
3.65
5.22
5.68
8.61
10.15
4.0
Accumulation Distribution
0.0117
N/A
N/A
96419.14
0.0105
N/A
N/A
N/A
Market Facilitation Index
0.05
N/A
N/A
0.0
0.06
N/A
N/A
N/A
Daily Balance Of Power
0.4
0.0
0.0
(0.17)
(0.17)
0.0
0.0
0.0
Period Momentum Indicator
0.02
N/A
N/A
(0.10)
(0.01)
N/A
N/A
N/A
Rate Of Daily Change
1.0
1.0
1.0
0.98
1.0
1.0
1.0
1.0
Day Median Price
4.26
8.05
3.65
5.3
5.68
8.61
10.15
4.0
Price Action Indicator
0.015
N/A
N/A
(0.30)
(0.01)
N/A
N/A
N/A
Relative Strength Index
85.39
89.81
54.56
59.25
61.39
75.56
49.72
81.98
Coefficient Of Variation
905.43
834.85
N/A
473.82
598.35
N/A
N/A
658.01
Mean Deviation
2.14
7.5
N/A
6.03
2.39
N/A
N/A
8.04
Jensen Alpha
0.7992
3.9
N/A
1.68
0.5936
N/A
N/A
3.33
Total Risk Alpha
0.2719
1.35
N/A
1.11
0.3264
N/A
N/A
1.77
Sortino Ratio
0.2647
0.816
N/A
0.2896
0.1689
N/A
N/A
0.6035
Downside Variance
8.96
18.49
N/A
33.06
10.22
N/A
N/A
31.94
Standard Deviation
7.76
29.83
N/A
8.19
3.62
N/A
N/A
22.86
Kurtosis
58.48
64.74
N/A
2.32
2.75
N/A
N/A
54.43
Potential Upside
2.33
5.09
N/A
14.49
7.28
N/A
N/A
10.42
Treynor Ratio
0.9724
(0.58)
N/A
2.12
36.69
N/A
N/A
1.37
Maximum Drawdown
62.14
241.38
N/A
42.56
17.14
N/A
N/A
179.17
Variance
60.16
889.72
N/A
67.15
13.08
N/A
N/A
522.81
Market Risk Adjusted Performance
0.9824
(0.57)
N/A
2.13
36.7
N/A
N/A
1.38
Risk Adjusted Performance
0.0903
0.0979
N/A
0.1643
0.1309
N/A
N/A
0.1215
Skewness
7.39
8.01
N/A
1.22
0.8455
N/A
N/A
7.1
Semi Deviation
1.42
1.63
N/A
5.02
2.34
N/A
N/A
3.27
Information Ratio
0.1021
0.1176
N/A
0.2032
0.1493
N/A
N/A
0.1492
Value At Risk
(2.52)
(2.49)
N/A
(8.38)
(4.75)
N/A
N/A
(7.26)
Expected Short fall
(2.97)
(9.75)
N/A
(7.36)
(2.79)
N/A
N/A
(11.66)
Downside Deviation
2.99
4.3
N/A
5.75
3.2
N/A
N/A
5.65
Semi Variance
2.03
2.66
N/A
25.19
5.48
N/A
N/A
10.7

Checkpoint Therapeutics Competition Performance Charts

Five steps to successful analysis of Checkpoint Therapeutics Competition

Checkpoint Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Checkpoint Therapeutics in relation to its competition. Checkpoint Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Checkpoint Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Checkpoint Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Checkpoint Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Checkpoint Therapeutics position

In addition to having Checkpoint Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Investor Favorites Thematic Idea Now

Investor Favorites
Investor Favorites Theme
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investor Favorites Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in Checkpoint Stock

If you are still planning to invest in Checkpoint Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Checkpoint Therapeutics' history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY